Under a tenth of people that would benefit from weight-loss injections including Wegovy can access them, states the global health agency as it issues its first recommendations on the drugs.
Given over a billion people worldwide now obese, it is advocating for increased and just access to this class of drugs.
According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our latest guidance affirms that obesity is a lifelong illness that can be treated with thorough and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are key obstacles to universal availability to the treatments that can assist patients in reducing considerable body mass, explains the organization.
GLP-1 Therapy Shortage
Despite the present most favorable outlook, the supply of such drugs might only reach about 100 million people – less than 10% of those who need them, according to the health organization.
The advice encourages nations and manufacturers to increase access, by approaches including voluntary licensing.
A patent on semaglutide – the core component of the drug Wegovy – is due to expire in multiple nations in 2026.
How Obesity Jabs Function
These medications imitate a body's own hormone to delay gastric emptying, curb appetite and enhance the sense of being full so users eat less.
Patients typically see weight reduction in the initial weeks of beginning the weekly injections.
Studies suggests patients may put most of the weight back on a year later of stopping the medication, because their normal appetite resume.
Being carrying excess weight elevates your chance for contracting diseases, such as type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Obesity impacts people in all nations and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.
